每日医刻|BD收入或超12亿元,荣昌新药授权眼科龙头;歌礼制药募资约4.7亿港元,用于肥胖症临床试验研发

财健道
Aug 20

将“财健道”设为星标持续关注,不错过好看每日医刻1BD收入或超12亿元,荣昌新药授权眼科龙头8月19日,荣昌生物宣布,与参天制药全资子公司参天中国达成协议,将公司具有自主知识产权的RC28-E注射液有偿许可给参天中国。根据协议,参天中国将获得RC28-E在大中华区及韩国、泰国、越南、新加坡、菲律宾、印度尼西亚及马来西亚的独家开发、生产和商业化权利,而荣昌生物将保留RC28-E在上述区域以外的全球...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10